PPARγ agonists such as pioglitazone and rosiglitazone have also been confirmed to exert neuroprotective effects in a range of Parkinson’s disease animal models, significantly improving motor and cognitive impairments in mouse (Lee et al., 2006; Agarwal et al., 2017; Kopp et al., 2022). Here, PPARG is linked to Parkinson disease.